Table 1.

Putative genetic associations with common metabolic AAEs studied from 2010 to 2015 and their related listings by expert PGx panels

Gene	Polymorphism	Putative association	Listings by expert panels	References
HTR2C	rs3813929 (759C/T)	T allele confers protection against AIWG	CPIC: evidence level Da PharmGKB: evidence level 2Bb	[42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55]
	rs1414334 (C/G)	C allele is associated with a higher risk of antipsychotic-induced MetS	CPIC: evidence level Da PharmGKB: evidence level 2Bb	[49, 61, 62, 63]
LEP	rs7799039 (2548G/A)	G allele acts dominantly to heighten susceptibility to AIWG	PharmGKB: evidence level 3c	[44, 46, 50, 52, 62, 73, 74, 75, 76, 77, 78]
LEPR	rs1137101 (Q223R) or (668A/G)	AIWG and related metabolic dysregulation; risk allele is unclear	PharmGKB: variant annotation	[52, 73, 74, 77, 78, 81]
MC4R	rs17782313 (C/T)	C allele linked to higher risk of AIWG	PharmGKB: evidence level 2Bb	[97, 98]
	rs489693 (A/C)	A allele linked to higher risk of AIWG	PharmGKB: evidence level 2Bb	[75, 93, 96]
MTHFR	rs1801131 (A1298C)	C allele associated with a greater risk of metabolic AAEs	PharmGKB: evidence level 3c	[109, 111, 112]
	rs1801133 (C677T)	T allele associated with a greater risk of metabolic AAEs	PharmGKB: evidence level 3c	[81, 106, 107, 108, 109, 110, 111, 112]
OGFRL1	rs9346455 (T/G)	T allele linked to higher risk of AIWG	PharmGKB: variant annotationd	[115]

References include both positive and negative findings. See references [19, 20] for further information on the PharmGKB and CPIC, as well as the criteria used to assign evidence levels.

^aConsidered of interest.

^bModerate evidence for this association.

^cLow evidence for this association.

^dListed under IBA57.